ArticleBMC gastroenterology2026
TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with unresectable advanced hepatocellular carcinoma (HCC), therapeutic options are limited, and transarterial chemoembolization (TACE) alone often yields suboptimal outcomes. This study aimed to evaluate clinical outcomes and recorded safety events associated with combining TACE, lenvatinib, and programmed cell death protein 1 (PD-1) inhibitors for HCC.
methodsA retrospective cohort study was conducted involving 209 patients with unresectable advanced HCC treated from June 2016 to December 2022. Patients were divided into the TACE + len group (n = 96) and the TACE + len+PD-1 group (n = 113). Tumor response, recorded adverse events, treatment exposure, OS, and PFS were analyzed. Propensity score-based IPTW was performed using baseline demographic and clinical variables to reduce measured baseline imbalance.
resultsAfter IPTW adjustment, baseline covariates achieved acceptable balance. Median OS was 16.49 months in the TACE + len+PD-1 group and 13.37 months in the TACE + len group; IPTW-weighted Cox regression showed an association between triple therapy and longer OS (HR = 0.591, 95% CI 0.417-0.836, P = 0.003). Median PFS was 10.02 months and 3.42 months, respectively, and the IPTW-weighted HR for PFS was 0.638 (95% CI 0.479-0.848, P = 0.002). Grade ≥ 3 adverse events occurred in 18.58% and 14.58% of patients, respectively (P = 0.440).
conclusionIn this exploratory retrospective cohort, adding PD-1 inhibitors to TACE plus lenvatinib was associated with improved tumor response and longer OS/PFS after IPTW adjustment, without a significant increase in recorded Grade ≥ 3 adverse events. These findings require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.